UK Markets closed

CVAC Jan 2024 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.48000.0000 (0.00%)
At close: 09:30AM EST
Full screen
Previous close2.4800
Open19.1000
Bid1.5000
Ask4.9000
Strike20.00
Expiry date2024-01-19
Day's range2.4800 - 2.4800
Contract rangeN/A
Volume1
Open interest43
  • EQS Group

    CureVac Welcomes Myriam Mendila as New Chief Development Officer

    Issuer: CureVac / Key word(s): Personnel01.02.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Welcomes Myriam Mendila as New Chief Development Officer Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experienceTÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribo

  • EQS Group

    CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®

    Issuer: CureVac / Key word(s): Patent31.01.2023 / 14:12 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technologyTÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V

  • EQS Group

    CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)

    Issuer: CureVac / Key word(s): Study30.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants i